CASCADIAN THERAPEUTICS

cascadian-therapeutics-logo

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase ... that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

#People #Financial #Website #More

CASCADIAN THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Therapeutics

Founded:
1985-01-01

Address:
Seattle, Washington, United States

Country:
United States

Website Url:
http://www.cascadianrx.com

Total Employee:
51+

Status:
Active

Contact:
206.801.2100

Email Addresses:
[email protected]

Total Funding:
64.9 M USD

Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Level 3 Communications Adobe Marketing Cloud CSC Global DNS


Current Employees Featured

scott-r-peterson_image

Scott R. Peterson
Scott R. Peterson Chief Scientific Officer @ Cascadian Therapeutics
Chief Scientific Officer

not_available_image

Robert L. Kirkman
Robert L. Kirkman President & CEO @ Cascadian Therapeutics
President & CEO

clay-siegall_image

Clay Siegall
Clay Siegall President, Chief Executive Officer, and Chairman of the Board @ Cascadian Therapeutics
President, Chief Executive Officer, and Chairman of the Board

roger-dansey_image

Roger Dansey
Roger Dansey Chief Medical Officer @ Cascadian Therapeutics
Chief Medical Officer
2018-05-01

scott-myers_image

Scott Myers
Scott Myers President, Chief Executive Officer and Director @ Cascadian Therapeutics
President, Chief Executive Officer and Director

Stock Details


Company's stock symbol is NASDAQ:CASC

Acquisitions List

Date Company Article Price
2014-08-11 Alpine Biosciences Alpine Biosciences acquired by Cascadian Therapeutics 27 M USD
2006-10-01 ProlX Pharmaceuticals Corp. ProlX Pharmaceuticals Corp. acquired by Cascadian Therapeutics N/A

Investors List

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Cascadian Therapeutics

biotechnology-value-fund_image

Biotechnology Value Fund

Biotechnology Value Fund investment in Post-IPO Equity - Cascadian Therapeutics

ayer-capital-management_image

Ayer Capital Management

Ayer Capital Management investment in Post-IPO Equity - Cascadian Therapeutics

kingsbrook-partners_image

Kingsbrook Partners

Kingsbrook Partners investment in Post-IPO Equity - Cascadian Therapeutics

cowen-group_image

Cowen Group

Cowen Group investment in Post-IPO Equity - Cascadian Therapeutics

hartz-mountain_image

Hartz Mountain Industries

Hartz Mountain Industries investment in Post-IPO Equity - Cascadian Therapeutics

ramius-capital_image

ArmaVir Partners

ArmaVir Partners investment in Post-IPO Equity - Cascadian Therapeutics

iroquois-capital_image

Iroquois Capital

Iroquois Capital investment in Post-IPO Equity - Cascadian Therapeutics

dafna-capital-management_image

Dafna Capital Management

Dafna Capital Management investment in Post-IPO Equity - Cascadian Therapeutics

downsview-capital_image

Downsview Capital

Downsview Capital investment in Post-IPO Equity - Cascadian Therapeutics

Official Site Inspections

http://www.cascadianrx.com

Unable to get host informations!!!

Loading ...

More informations about "Cascadian Therapeutics"

Oncothyreon Announces Corporate Name Change to โ€ฆ

Jun 8, 2016 Investor Contact: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Tricia Truehart The Trout Group 646-378-2953 [email protected] Media Contact: Amy Bonanno BMC ...See details»

Cascadian Therapeutics, Inc. Company Profile | Seattle, WA ...

Find company research, competitor information, contact details & financial data for Cascadian Therapeutics, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»

Cascadian Therapeutics - Crunchbase Company Profile & Funding

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.See details»

Cascadian Therapeutics, Inc. | LinkedIn

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer.See details»

Cascadia RX Insights

Cascadia exists to optimize healthcare delivery to improve patient outcomes. We believe that integrated care is better care and ultimately what each patient deserves.See details»

Oncothyreon Announces Corporate Name Change to Cascadian โ€ฆ

Jun 8, 2016 Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian Therapeutics,See details»

Cascadian Therapeutics, Inc. Information - RocketReach

Our most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor. We are headquartered in Seattle, Washington. For more information, visit โ€ฆSee details»

Oncothyreon Announces Corporate Name Change to Cascadian โ€ฆ

SEATTLE, June 08, 2016 (GLOBE NEWSWIRE) โ€” Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its โ€ฆSee details»

Nextsource | Company Profile | Cascadian Therapeutics

Explore the company profile of Cascadian Therapeutics (cascadianrx.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»

Cascadian Therapeutics - PitchBook

Cascadian Therapeutics General Information Description. Provider of clinical-stage biopharmaceutical services intended to develop and commercialize novel targeted compounds.See details»

Cascadian Therapeutics - VentureRadar

Cascadian Therapeutics VentureRadar profile. Find out more about Cascadian Therapeutics, Healthcare and Biopharma.See details»

Cascadian Therapeutics, Inc. | Insights

Jan 21, 2021 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»

Cascadian Therapeutics Inc Overview | Salary.com

Discover essential details about Cascadian Therapeutics Inc, including address, contact, and journey of our company's evolution.See details»

Cascadian Therapeuticsโ€™s Competitors, Revenue, Number of

Cascadian Therapeuticsโ€™s Profile, Revenue and Employees. Cascadian engages in the development of oncology products for the treatment of cancer. Cascadian Therapeuticsโ€™s โ€ฆSee details»

Oncothyreon (ONTY) Changes Name to Cascadian Therapeutics; โ€ฆ

Jun 8, 2016 Oncothyreon Inc. (Nasdaq: ONTY) (Nasdaq: CASC) announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the...See details»

Directory of Cascadia Organizations

Cascadia Times. Founded in 1995, Cascadia Times has defined bioregional environmental journalism for nearly a quarter century. Founded by Paul Koberstein and Kathie Durbin, โ€ฆSee details»

Oncothyreon Announces Corporate Name Change To Cascadian

Jun 8, 2016 Employer Resources; Best Places to Work; Post Jobs; Talent Solutions; Advertise; Submit a Press ReleaseSee details»

Cascadia Organizations - Regenerate Cascadia

Regenerate Cascadia is a social movement and capacity-building organization developing a vision and framework to administer a regeneration fund for Cascadia, a bioregion located โ€ฆSee details»

Oncothyreon Announces Corporate Name Change To Cascadian

Jun 8, 2016 The webcast will be available on the Events and Presentations Page of the Companyโ€™s website at www.cascadianrx.com. No action is required by stockholders with โ€ฆSee details»

History of the Cascadia Movement - Regenerate Cascadia

Regenerate Cascadia is a social movement and capacity-building organization developing a vision and framework to administer a regeneration fund for Cascadia, a bioregion located โ€ฆSee details»

linkstock.net © 2022. All rights reserved